article thumbnail

The essential role of recombinant phage display antibody libraries

Drug Target Review

Since the 1970s, when hybridoma technology enabling the generation of monoclonal antibodies (mAbs) was first developed, 1 antibody-based therapeutics have become one of the most rapidly growing drug categories, with applications across cancer indications, immune disorders and infections. Antibodies to watch in 2024. 2024 Jan 5;16(1).

article thumbnail

AI At The Frontier: Empowering Early Career Professionals In Drug Discovery

Elrig

My role involved generating and characterizing complex proteins critical for biological assay development, hit discovery, and structural biology. This involved designing and implementing biological strategies, encompassing target validation, hit identification, establishing assays, and collaborating on structural work.

article thumbnail

Article EMA Thank You EMA finalizes clinical anticancer therapeutic guidance update

Agency IQ

The revisions flesh out considerations for use of biomarkers at all stages of product development and add new content on rare cancers and platform trial designs. BY KIRSTEN MESSMER, PHD, RAC, KARI OAKES | JAN 31, 2024 9:01 PM CST Regulatory Background Cancer is the second leading cause of death in the E.U. were from cancer.